Anti-Fungal Drugs Market 2019 Global Players: ABBOTT LABORATORIES, PFIZER, GLAXOSMITHKLINE, BAYER HEALTHCARE, NOVARTIS, SANOFI-AVENTIS, KRAMER LABORATORIES, ENZON PHARMACEUTICALS

Antifungal drugs are used to cure fungal infections, which occur due to unclean, unhygienic, and damp environment. Fungal infections are caused by microscopic organisms invading epithelial tissue. Systemic fungal infections are usually caused by the indigestion or inhalation of fungus spores and cause fungal pneumonia, and opportunistic fungus causes diseases, such as candidiasis, meningitis, mucormycosis, etc. The global anti-fungal drugs market is expected to register a CAGR of 3.7% during the forecast period, 2018 to 2023.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16690
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Increasing Number of Anti-fungal Drugs as Over-The-Counter (OTC)
With rising popularity of over-the-counter (OTC) drugs, many patients prefer them to obtaining a prescription from a healthcare professional. Numerous common and harmless fungal infections are left untreated by patients, owing to medical costs and logistical constraints. These have directly contributed to the rise in the usage of OTC drugs, as these infections can be treated by OTC drugs, owing to their ease of availability.
Increasing awareness about myriad fungal infections and increasing government and corporate funding are some other drivers of the market.

Major Players:
ABBOTT LABORATORIES, PFIZER, GLAXOSMITHKLINE, BAYER HEALTHCARE, NOVARTIS, SANOFI-AVENTIS, MERCK & CO., KRAMER LABORATORIES, ENZON PHARMACEUTICALS, GILEAD amongst others.

Request Discount on this report @ https://marketprognosis.com/discount-request/16690
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Presence of Generics and Government Regulations in the Pharmaceutical Industry
Although there is an increase in the sales of anti-fungal generic drugs, the market value of these drugs has decreased, as the price of generics is almost 20 to 50% of the branded drugs. To meet the market value, the sales of generics must be increased by at least four times to that of branded drugs. Even with the increasing volume of generic anti-fungal drug sales, the overall market value of anti-fungal drugs has reduced.
Additionally, high penetration of conventional drugs used for treatment and allergic reaction to some types of anti-fungal drugs are also restraining the market growth.

North America to Dominate the Market
The global anti-fungal drugs market is segmented by drug type, therapeutic indication, and geography. By geography, it is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.
North America dominates the market due to increasing awareness of fungal infections with the growing incidence of antifungal infections and increasing government and corporate funding in the industry.

Enquiry Before Buying@ https://marketprognosis.com/enquiry/16690
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMarkPvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.